US4350683A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antibody production from hybrid cell line
Assignee: BTG International Ltd
•
Filing: 1980-01-03
•
Granted: 1982-09-21
•
Expires: 2000-01-03
Abstract
Abstract Hybrid cell lines for providing antibodies are produced from a rat myeloma cell line having the C.N.C.M. designation I-078. In production of the hybrid cells, the rat myeloma cell line is fused with immunocyte cells such as spleen cells from an animal such as a rat sensitized to an immunogen. Use of the rat myeloma cell line is particularly advantageous for in vivo cultivation of a hybrid cell line to produce antibodies.
Inventors
- 👤 Giovanni Galfre
- 👤 Cesar Milstein
- 👤 Bruce W. Wright
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 00:11
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/10; C12N5/12; C12N5/16; C07; C07K; C07K16/00; C12N1/00; C12P; C12P1/00; C12R; C12R2001/00; C12R2001/91
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
12 words
A substantially pure rat myeloma cell line having the C.N.C.M. designation I-078.
Claim 2
Dependent Claim
12 words
A substantially pure rat myeloma cell line having the C.N.C.M. designation I-078.
Claim 3
Dependent Claim
48 words
A hybrid cell line prepared from cells of the cell line C.N.C.M. I-078 through the fusion thereof with immunocyte cells from an animal sensitized to an immunogen in a nutrient medium for said cells, followed by isolation of the hybrid cell line from the resultant mixture of cells.
Claim 4
Dependent Claim
48 words
A hybrid cell line prepared from cells of the cell line C.N.C.M. I-078 through the fusion thereof with immunocyte cells from an animal sensitized to an immunogen in a nutrient medium for said cells, followed by isolation of the hybrid cell line from the resultant mixture of cells.
Claim 5
Dependent Claim
22 words
An in vitro cell culture system comprising a substantially pure rat myeloma cell line designated C.N.C.M. I-078 in a nutrient medium therefor.
Claim 6
Dependent Claim
22 words
An in vitro cell culture system comprising a substantially pure rat myeloma cell line designated C.N.C.M. I-078 in a nutrient medium therefor.
Claim 7
Dependent Claim
40 words
A cell fusion system which comprises cells of the cell line C.N.C.M. I-078 and immunocyte cells from an animal sensitized to an immunogen in a nutrient culture medium therefor together with an agent which promotes the fusion of said cells.
Claim 8
Dependent Claim
40 words
A cell fusion system which comprises cells of the cell line C.N.C.M. I-078 and immunocyte cells from an animal sensitized to an immunogen in a nutrient culture medium therefor together with an agent which promotes the fusion of said cells.
Claim 9
Dependent Claim
16 words
The cell fusion system according to claim 4, in which the immunocyte cells are spleen cells.
Claim 10
Dependent Claim
16 words
The cell fusion system according to claim 4, in which the immunocyte cells are rat cells.
Claim 11
Dependent Claim
19 words
The cell fusion system according to claim 4, in which the agent which promotes the fusion is polyethylene glycol.
Claim 12
Dependent Claim
37 words
The cell fusion system according to claim 4 which comprises cells of the cell line C.N.C.M. I-078 and spleen cells from a rat sensitized to an immunogen in a nutrient culture medium therefor together with polyethylene glycol.
Claim 13
Dependent Claim
41 words
A process for producing the hybrid cell line of claim 2, which comprises fusing cells of the cell line C.N.C.M. I-078 with immunocyte cells from an animal sensitized to an immunogen using an agent which promotes the fusion of said cells.
Claim 14
Dependent Claim
21 words
The process according to claim 9, in which the animal is sensitized to the immunogen by administration of the immunogen thereto.
Claim 15
Dependent Claim
36 words
A process for the production of antibodies which comprises culturing cells of the cell line of claim 2 in an in vitro or in vivo culture medium therefor and thereafter isolating the antibodies from said medium.
Claim 16
Dependent Claim
55 words
An antibody production process which comprises preparing the hybrid cell line of claim 2 by the fusion of cells of the cell line C.N.C.M. I-078 with immunocyte cells sensitized to an immunogen and culturing the hybrid cell line in an in vitro or in vivo culture medium therefor to produce antibodies against the sensitizing immunogen.
Claim 17
Dependent Claim
32 words
The process according to claim 12, in which the immunocyte cells are sensitized to the immunogen by the administration of the immunogen to an animal from which the immunocyte cells are obtained.
Claim 18
Dependent Claim
20 words
The process according the claim 13, in which the animal from which the immunocyte cells are obtained is a rat.
Claim 19
Dependent Claim
46 words
The process according to claim 11 in which cells of the hybrid cell line are cultured by inoculating a rat with the cell line to thereby produce a solid or ascitic tumor, and thereafter isolating the antibodies from the serum or ascitic fluid of the rat.
References Cited (Backward Citations)
US4196265A
Cited
US4172124A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-20 | 1986-03-22 | 1986-09-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-20 | 1990-03-22 | 1990-09-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-20 | 1994-03-22 | 1994-09-21 | $7700.00 | Window Closed / Lapsed |